Femasys stock.

FEMASYS INC. EMPLOYEE STOCK PURCHASE PLAN 1. SECTION 1. PURPOSE OF THE PLAN. The Femasys Inc. Employee Stock Purchase Plan (the “Plan”) is intended to provide Eligible Employees (as defined below) the opportunity to increase their proprietary interest in Femasys Inc. (the “Company”) by conveniently purchasing shares of the …Femasys Inc. (NASDAQ: FEMY) shares were stationery Thursday, as the biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of products, announced ...Nov 30, 2023 · According to 3 stock analysts, the average 12-month stock price forecast for Femasys stock is $9.00, which predicts an increase of 845.18%. The lowest target is $7.00 and the highest is $10. On average, analysts rate Femasys stock as a strong buy. You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.

That’s a massive surge in trading volume compared to Femasys’ daily average of about 3.3 million shares. FEMY stock is up 180.9% as of Tuesday morning after closing out Monday down 63.2% year ...Femasys stock price prediction is an act of determining the future value of Femasys shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation.The successful prediction of Femasys' future price could yield a significant profit. Please, note that this module is not intended to be used solely to …

- FemaSeed ® is the first-ever, first-line approach designed to deliver sperm directly where conception occurs -. ATLANTA, April 18, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health, today announced the ...

In a concurrent private placement, Femasys has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 3,196,722 shares of common stock. The offering is expected to close on or about April 20, 2023, subject to the satisfaction of customary closing conditions.ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the …Femasys Inc Follow Share $1.03 After Hours: $1.06 (2.91%) +0.030 Closed: Nov 24, 4:59:11 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Soleno Therapeutics Inc $28.87 SLNO3.11% Novo... LAS VEGAS, November 15, 2023--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company") announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) ("Femasys"), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions ...

146.71. +1.95%. 45.70M. View today's Femasys Inc stock price and latest FEMY news and analysis. Create real-time notifications to follow any changes in the live stock price.

FEMY - Femasys Inc Stock Price and Quote. Nov-23-23 03:38PM. 20 Countries with the Highest Teenage Pregnancy Rates. (Insider Monkey) Nov-15-23 08:30AM. PharmaCyte Biotech Acquires $5 Million Stake in Emerging Womens Health Innovator Femasys, Inc. Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by ...

Femasys Inc. (NASDAQ: FEMY) shares are trading higher Friday after HC Wainwright maintained a Buy rating on the stock and raised its price target from $5 to $13.Femasys Inc. FEMY shares are up more than 14% on Monday and have gained more than 900% over the last five days. Here's a look at what's going on:. What To Know: HC Wainwright & Co. analyst Emily Bodnar maintained Femasys with a Buy rating and raised the price target from $5 to $13 on Friday.. Femasys also announced last …Femasys Inc, a medical technology company, has been attracting attention from investors due to its positive stock performance on October 2, 2023. According to data from CNN Money, the company has received favorable price forecasts from four analysts, with a median target of $8.50. The high estimate is $13.00, while the low estimate is $5.00.Femasys to Participate in the H.C. Wainwright 25th Annual Global Investment Conference. 08/31/2023. Femasys Inc. Obtains Medical Device Establishment License from Health Canada. 08/10/2023. Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update. 08/03/2023.Based on short-term price targets offered by three analysts, the average price target for Femasys Inc. comes to $9.00. The forecasts range from a low of $5.00 to a high of $12.00. The average ...

- The 510(k) Clearance from the United States Food and Drug Administration (FDA) allows for the U.S. commercialization of FemaSeed ®, an intratubal artificial insemination option designed to augment the natural fertilization process - - FemaSeed ® is an innovative infertility treatment designed to deliver sperm directly to where conception …In a concurrent private placement, Femasys has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 3,196,722 shares of common stock.Femasys ( NASDAQ: FEMY) shares jumped 21% midday Monday following news that the US Food and Drug Administration has approved its investigational device exemption application to begin clinical ...ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) — Femasys Inc. FEMY, a biomedical company focused on meeting significant unmet needs for women worldwide with a broad …WebUnder the terms of the investment, the investors were also issued two series of warrants: warrants to purchase approximately 5.8 million shares of common stock at an exercise price of $1.18 per share expiring one year from issuance and warrants to purchase approximately 5.8 million shares of common stock at an exercise price of $1.475 per …What To Know: HC Wainwright & Co. analyst Emily Bodnar maintained Femasys with a Buy rating and raised the price target from $5 to $13 on Friday. Femasys also announced last week that it has ...The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. In depth view into FEMY (Femasys) stock including the latest price, news, dividend history, earnings information and financials.

Apr 19, 2023 · In a concurrent private placement, Femasys has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 3,196,722 shares of common stock. The offering is expected to close on or about April 20, 2023, subject to the satisfaction of customary closing conditions.

Nov 24, 2023 · Complete Femasys Inc. stock information by Barron's. View real-time FEMY stock price and news, along with industry-best analysis. On average, Wall Street analysts predict. that Femasys's share price could reach $9.00 by Nov 14, 2024. The average Femasys stock price prediction forecasts a potential upside of 821.19% from the current FEMY share price of $0.98. Femasys was previously notified by Nasdaq on June 1, 2023 that it was not in compliance with the minimum bid price rule (“the Rule”) because its common stock failed to meet the closing bid ...Femasys ®, FemBloc ® ... 10,000,000 shares of our common stock that are available for future issuance under our 2021 Equity Incentive Plan, or our 2021 Plan, which will become effective on the day immediately prior to the date the registration statement of which this prospectus forms a part is declared effective, ...ATLANTA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office ...PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (PharmaCyte or the Company) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (Femasys), a biomedical company focused on meeting... Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update Globe Newswire • …

Femasys expects the resulting patent, when issued, will have an anticipated expiration in 2039, at the earliest. In October, Femasys regained compliance with Nasdaq’s minimum bid price requirement, after having received a notice on June 1, 2023 from Nasdaq that they were not in compliance with such requirement.

Shares Outstanding 21.65 M Public Float 19.48 M Yield FEMY is not currently paying a regular dividend. Latest Dividend N/A Ex-Dividend Date N/A Short Interest (10/31/23) …Web

Discover historical prices for FEMY stock on Yahoo Finance. View daily, weekly or monthly format back to when Femasys Inc. stock was issued. ... Femasys Inc. (FEMY) NasdaqCM - NasdaqCM Real Time ...Nov 29, 2023 · Femasys GAAP EPS of -$0.22 misses by $0.02, revenue of $0.32M misses by $0.05M SA News Thu, Aug. 10 Femsys stock jumps 21% after FDA green lights FemBloc testing Nov. 30, 2023 5:40 PM ET Femasys Inc. (FEMY) By: Tiyashi Datta, SA News Editor. Femasys ( NASDAQ: FEMY) filed a prospectus related to the offer and resale by the selling stockholders of up to an ...Femasys Inc. Common Stock (FEMY) 0 Add to Watchlist Add to Portfolio Quotes Summary Real-Time After-Hours Live Key Data Bid Price and Ask Price The bid & ask refers to the …WebThe past week has seen Femasys Inc. (FEMY), a company known for its work in the healthcare sector, experience fluctuations in its stock price. With a 52-week range of $0.2480 - $4.7500 and an average volume of 14,323,125, the stock's performance has been intriguing. Photo by Afif Ramdhasuma on Unsplash. Factors driving this week's …View Our Latest Stock Analysis on FEMY. Femasys Price Performance. FEMY opened at $0.96 on Monday. The business has a fifty day moving average of $1.25 and a 200 day moving average of $0.81. Femasys has a 52-week low of $0.25 and a 52-week high of $4.75. The company has a quick ratio of 8.28, a current ratio of 4.68 and a …Nov 30, 2023 · Why Is Femasys (FEMY) Stock Up 181% Today? investorplace.com - September 26 at 9:11 AM. Femasys up 205% as FDA clears fertility treatment. seekingalpha.com - September 25 at 11:56 PM. Femasys Secures FDA 510 (k) Clearance To Market FemaSeed. markets.businessinsider.com - September 25 at 6:56 PM. What To Know: HC Wainwright & Co. analyst Emily Bodnar maintained Femasys with a Buy rating and raised the price target from $5 to $13 on Friday. Femasys also announced last week that it has ...52 Wk Low 0.25 52 Wk High 4.75 Avg. Volume 1,640,879 Market Cap 22.30 M Dividend 0.00 ( 0.00%) Beta NA Key Earnings Data Earnings ESP 0.00%Web

The downside is that many penny stocks are active for no good fundamental reason and have only volatility to offer investors. FEMY’s Market Performance. Femasys Inc (FEMY) has experienced a 3.06% rise in stock performance for the past week, with a -36.36% drop in the past month, and a 113.56% rise in the past quarter.That’s a massive surge in trading volume compared to Femasys’ daily average of about 3.3 million shares. FEMY stock is up 180.9% as of Tuesday morning after closing out Monday down 63.2% year ...Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Instagram:https://instagram. best options trading booksbank of america cryptowellington vanguard fundhow much is a 1964 kennedy half dollar Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical OfficerWeb vanguard money market fund yieldhome loans for single parents Our Vision. Femasys is working to provide next generation advancements to disrupt severely under-served areas in women’s health. Technological advancements in female reproductive health are long overdue, driving our focus in permanent birth control and front-end infertility.LAS VEGAS, November 15, 2023--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company") announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) ("Femasys"), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions ... carrier global corp. Femasys is a biomedical company focused on meeting significant unmet needs for women worldwide by developing two lead revolutionary product candidates in late-stage clinical development for ...ATLANTA, May 11, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include ...Detailed statistics for Femasys Inc. (FEMY) stock, including valuation metrics, financial numbers, share information and more. Detailed statistics for Femasys Inc. (FEMY) ... The stock price has decreased by -20.16% in the last 52 weeks. The beta is -3.54, so Femasys's price volatility has been lower than the market average. Beta (1Y)